MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.clineuro.2019.01.007

Медицинская библиотека · Clinical neurology and neurosurgery · 2019

Experiences of an outpatient infusion center with intravenous magnesium therapy for status migrainosus.

Xu Fanny, Arakelyan Anush, Spitzberg Andrew, Green Lauren, Cesar Paul-Henri, Csere Anne, Nworie Olive, Sahai-Srivastava Soma

СтатьяНаблюдательное исследованиеПеревод в очереди

Аннотация

OBJECTIVES

Exploratory study to investigate the effectiveness of intravenous magnesium as an abortive for status migrainosus in an outpatient infusion center, and characterize the patients who benefit from the therapy.

PATIENTS &

METHODS

Retrospective analysis of 234 migraine patients who received IV magnesium as a headache abortive, at the headache clinic of University of Southern California. Additional intramuscular (IM) injections for nausea (prochlorperazine, odansetron, metoclopramide) or for refractory pain (ketorolac, dexamethasone, sumatriptan, dihydroergotamine), were administered as necessary. Immediately before and after treatment, self-reported pain levels were recorded using an 11-point numeric pain rating scale (0-10).

RESULTS

Our patient sample has a mean age of 44 years and was predominantly female (79%). 36 (19%) had migraine with aura. Overall, pain score decreased from 5.46±2.39 to 3.56 ± 2.75 (P < 0.001) after magnesium infusion. One hundred twenty-seven (54%) patients had clinically significant pain reduction, as defined by pain decrease ≥ 30%. One hundred and four patients (44%) received IV magnesium and did not require additional intramuscular (IM) medications for pain. In patients who did not receive additional IM medications for pain, pain score decreased from 4.76 ± 2.41 to 2.95 ± 2.70 (p < 0.001), and 61 out of 104 (59%) experienced ≥ 30% pain reduction. Patients with less severe pain tended to have a better response than patients with more severe pain, as patients with ≥30% pain reduction had a significantly lower pre-treatment pain score (p = 0.018).

CONCLUSION

For a subset of patients with status migrainosus, IV magnesium therapy results in clinically significant pain relief without the need for intramuscular pain medications. Therefore, IV magnesium may be useful as a cost-effective first-line parental therapy for status migrainosus, especially for patients who initially present with lower pain intensity.

Для цитирования: Xu Fanny, Arakelyan Anush, Spitzberg Andrew, Green Lauren, Cesar Paul-Henri, Csere Anne, Nworie Olive, Sahai-Srivastava Soma. Experiences of an outpatient infusion center with intravenous magnesium therapy for status migrainosus.. Clinical neurology and neurosurgery. 2019. DOI: 10.1016/j.clineuro.2019.01.007.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.